UroGen Pharma (URGN) FCF Margin (2017 - 2026)

UroGen Pharma (URGN) has 10 years of FCF Margin data on file, last reported at 93.5% in Q1 2026.

• Quarterly FCF Margin rose 11291.0% year-over-year to 93.5% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 123.04% (down 730.0% YoY) and the FY2025 annual result came in at 152.13%, down 4668.0% from the prior year.
• FCF Margin rose to 93.5% in Q1 2026, from 97.07% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 55.18% in Q4 2023 to a low of 206.41% in Q1 2025.
• A 5-year average of 124.46% and a median of 112.87% in 2022 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2022 — FCF Margin surged 19176 bps — and 2025, when it tumbled 6693 bps.
• Tracing URGN's FCF Margin over 5 years: stood at 121.72% in 2022, then soared by 55 bps to 55.18% in 2023, then retreated by 2 bps to 56.33% in 2024, then slumped by 72 bps to 97.07% in 2025, then climbed by 4 bps to 93.5% in 2026.
• The last three FCF Margin figures came in at 93.5% (Q1 2026), 97.07% (Q4 2025), and 175.49% (Q3 2025), per Business Quant data.